Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk
- 26 March 2020
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 382 (13), 1208-1218
- https://doi.org/10.1056/nejmoa1910021
Abstract
Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal stents in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use of polymer-based drug-eluting stents, as compared with polymer-free drug-coated stents, in such patients are limited.Keywords
Funding Information
- Medtronic (Funded the ONYX ONE Trial)
This publication has 19 references indexed in Scilit:
- Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCIJAMA, 2019
- Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding RiskEuropean Heart Journal, 2019
- Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trialsThe Lancet, 2019
- 2018 ESC/EACTS Guidelines on myocardial revascularizationEuroIntervention, 2019
- Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) StudyAmerican Heart Journal, 2018
- Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trialThe Lancet, 2018
- Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding RiskThe New England Journal of Medicine, 2015
- Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent CandidatesJournal of the American College of Cardiology, 2015
- Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary StentsThe New England Journal of Medicine, 2010
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingThe New England Journal of Medicine, 1998